



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁵ : G01N 33/569, 33/53, 33/532 | A1 | (11) International Publication Number: WO 92/02820 (43) International Publication Date: 20 February 1992 (20.02.92) |
| (21) International Application Number: PCT/US91/05310 (22) International Filing Date: 26 July 1991 (26.07.91) (30) Priority data: 559,867 27 July 1990 (27.07.90) US (60) Parent Application or Grant (63) Related by Continuation US Not furnished (CIP) (71) Applicant (for all designated States except US): WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, Madison, WI 53705 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : DOYLE, Michael, P. [US/US]; 107 Stonington Drive, Peachtree City, GA 30269 (US). PADHYE, Nisha [IN/US]; 21 Laramie Court, Madison, WI 53719 (US). | | (74) Agent: SARA, Charles, S.; Andrus, Sceales, Starke & Sawall, 100 East Wisconsin Avenue, Suite 1100, Milwaukee, WI 53202 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> |
| (54) Title: MONOCLONAL ANTIBODY TO ENTEROHEMORRHAGIC ESCHERICHIA COLI 0157:H7 AND 026:H11 AND METHOD FOR DETECTION (57) Abstract A monoclonal antibody specific for enterohemorrhagic <i>Escherichia coli</i> 0157:H7 and 026:H11 is produced by immunizing BALB/c mice with a strain of <i>E. coli</i> 0157:H7. The antibody reacts strongly by an enzyme-linked immunosorbent assay with an approximately 5,000 - 6,000 dalton molecular weight outer membrane protein of strains of enterohemorrhagic <i>Escherichia coli</i> 0157:H7 and 026:H11. A rapid and sensitive assay for detecting these organisms is also disclosed. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|-----------------|--------------------------|
| AT | Austria | ES | Spain | MG | Madagascar |
| AU | Australia | FI | Finland | ML | Mali |
| BB | Barbados | FR | France | MN | Mongolia |
| BE | Belgium | GA | Gabon | MR | Mauritania |
| BF | Burkina Faso | GB | United Kingdom | MW | Malawi |
| BG | Bulgaria | GN | Guinea | NL | Netherlands |
| BJ | Benin | GR | Greece | NO | Norway |
| BR | Brazil | HU | Hungary | PL | Poland |
| CA | Canada | IT | Italy | RO | Romania |
| CF | Central African Republic | JP | Japan | SD | Sudan |
| CG | Congo | KP | Democratic People's Republic of Korea | SE | Sweden |
| CH | Switzerland | | | SN | Senegal |
| CI | Côte d'Ivoire | KR | Republic of Korea | SU ⁺ | Soviet Union |
| CM | Cameroon | LI | Liechtenstein | TD | Chad |
| CS | Czechoslovakia | LK | Sri Lanka | TG | Togo |
| DE | Germany | LU | Luxembourg | US | United States of America |
| DK | Denmark | MC | Monaco | | |

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

-1-

MONOCLONAL ANTIBODY TO ENTEROHEMORRHAGIC
ESCHERICHIA COLI 0157:H7 AND 026:H11
AND METHOD FOR DETECTION

Field of the Invention

The present invention relates generally to hybridoma cell lines developed to produce monoclonal antibodies and, more specifically, to a cell line producing monoclonal antibodies to enterohemorrhagic Escherichia coli 0157:H7 (E. coli 0157:H7) and Escherichia coli 026:H11 (E. coli 026:H11).

Description of the Prior Art

E. coli 0157:H7 was first recognized as an important human pathogen in the United States in 1982, when the organism was diagnosed as the cause of two geographically separate outbreaks of hemorrhagic colitis, both associated with eating undercooked beef from a particular fast-food chain, (Riley, Lee W. et al, 1983, "Hemorrhagic Colitis Associated With A Rare Escherichia Coli Serotype," The New England Journal of Medicine, Vol. 308, No. 12, pgs. 681-685). These outbreaks of unusual gastrointestinal illness were characterized by the sudden onset of severe abdominal cramps and grossly bloody diarrhea with no fever or low grade fever. Such illnesses have been associated with E. coli 0157:H7 and also E. coli 026:H11 (Levine, M.M. 1987, "Escherichia coli that Cause Diarrhea: Enterotoxigenic, Enteropathogenic, Enteroinvasive, Enterohemorrhagic, and Enteroadherent," Journal of Infectious Diseases, Vol. 155. pgs. 377-389; Levine, M.M., et al., 1987, "A DNA Probe to Identify Enterohemorrhagic Escherichia coli of 0157:H7 and Other Serotypes that Cause Hemorrhagic Colitis and Hemolytic Uremic Syndrome," Journal of Infectious Diseases, Vol. 156, pgs. 175-182). These bacteria are termed enterohemorrhagic E. coli.

The E. coli organism produces toxins, known as verotoxins, that cause significant intestinal bleeding in several mammals, including humans. The spectrum of

-2-

illnesses associated with E. coli 0157:H7 infections ranges from asymptomatic infections to non-bloody diarrhea, hemorrhagic colitis, hemolytic uremic syndrome and death (Ryan, Caroline A. et al, 1986, "Escherichia coli 0157:H7 Diarrhea in a Nursing Home: Clinical, Epidemiological, and Pathological Findings," Journal of Infectious Diseases, Vol. 154, No. 4, pgs. 631-638). Hemolytic uremic syndrome is defined as the sudden onset of hemolytic anemia, thrombocytopenia and acute renal failure after the appearance of symptoms in the upper respiratory tract, stomach or intestines. Hemolytic uremic syndrome is generally the end result of a number of different and inciting events and pathogenic mechanisms.

The organism has been isolated from meat and poultry and unpasteurized milk. A variety of reports suggest that foods, particularly foods of animal origin, may be an important source of E. coli 0157:H7 infections (Doyle, Michael P. and Jean L. Schoeni, 1987, "Isolation of Escherichia Coli 0157:H7 from Retail Fresh Meats and Poultry," Applied and Environmental Microbiology, Vol. 53, No. 10, pgs. 2394-2396).

Because most of the outbreaks of hemorrhagic colitis have been food related, there is a need for a rapid, sensitive and specific assay for detecting E. coli 0157:H7 and E. coli 026:H11. Presently, the available methods for detecting the organism in foods are time consuming or are not highly specific. For example, the Food Research Institute, Madison, Wisconsin, is currently being used by many agencies for the detection of the E. coli 0157:H7 organism. The process utilized by the Food Research Institute, however, involves a complicated, multi-day procedure described in Doyle and Schoeni (supra). Doyle and Schoeni have tested a variety of meats and found the organism in about 1% or 2% of the meats tested. The organism can also be isolated from

-3-

feces, raw milk, etc. Eggs from experimentally infected chickens are also contaminated on the surface.

In order to assay the organism, the first step is to enrich the organism in the food sample. Because the food sample may have minor amounts of the organism, a condition which should repress other forms of bacteria and increase the numbers of the desired organism. The enrichment medium has selective agents which are selective for gram-negative bacteria, including E. coli 0157:H7. The medium is then incubated overnight at 37°C.

The incubated sample is then run through a hydrophobic grid membrane filter paper (HGMF). The filter paper is subdivided into about 1,400-1,600 little squares. Wax is used to mark the filter off. The wax keeps the colonies isolated. The filter is then removed and placed on a piece of nitrocellulose paper. The nitrocellulose paper will be placed over some of the medium with agar that contains the same selective agents as in the enrichment medium. This plate is then incubated at 37°C overnight. This allows the colonies to develop on the filter paper. The filter paper is then removed and saved. The toxins are trapped in the nitrocellulose paper. As they grow, they develop by an immunoblot procedure which employs antibodies produced in rabbits to the toxins. After the blots are developed, spots are observed on the paper where toxin is present. The spots on the HGMF are matched with the bacterial colonies on the paper.

coli 0157:H7 by biochemical or other tests. After the sample in a selective enrichment medium. The organism is then isolated in a series of procedures. The separated isolates grow to produce toxins which diffuse into and are entrapped in an underlying filter paper. The toxins

SUBSTITUTE SHEET

-4-

are then detected using antibody to the toxins as a reagent. Bacterial colonies on the overlying filter paper with grids are aligned with the filter paper showing spots with toxin. Colonies that produced toxin are identified by standard taxonomic procedures.

Although the procedure can effectively isolate E. coli 0157:H7 from food samples inoculated with low levels of the organism, the method is not amenable to routine testing because of complexity and extensive need for personnel time.

Other tests, such as one developed by Health and Welfare Canada, are being developed. The Canadian test uses a monoclonal antibody to E. coli 0157, but it is not a specific test because it cross-reacts with other enterics, such as Salmonella Group N and unimportant E. coli 0157 strains that are not H7. (Todd, E.C.D. et al, 1988, "Rapid Hydrophobic Membrane Filter-Enzyme Labeled Antibody Procedure for Identification and Enumeration of Escherichia coli 0157:H7 in Foods" Applied and Environmental Microbiology, Vol. 54, pgs. 2536-2540.)

Gene-probe based assays have been developed which are based on binding DNA that encodes for verotoxins (Levine, M.M., et al., supra. 1987). Hence, all verotoxin-producing E. coli are detected by this procedure rather than solely enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11.

Summary of the Invention

It is an object of the present invention to produce a monoclonal antibody that is highly specific for enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11.

It is further an object of the present invention to develop a test for using a monoclonal antibody to assay E. coli 0157:H7 and E. coli 026:H11 in which the procedure is shortened to a usable period of time, e.g., under one day.

-5-

It is further an object of the present invention to develop an immunoassay for the rapid detection of E. coli 0157:H7 and E. coli 026:H11 in food and fecal specimens.

5 It is another object of the present invention to develop a procedure to isolate E. coli 0157:H7 and E. coli 026:H11 from foods or other samples and to determine the prevalence of the organisms in the samples.

10 It is another object of this present invention to use a specified outer membrane protein of enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 as a marker to identify strains of enterohemorrhagic E. coli. Assays, including ELISA, based on monoclonal antibody specific to this marker, will be used to detect and
15 differentiate enterohemorrhagic E. coli isolated from foods, environmental and clinical specimens.

It is further an object of the present invention to provide for the synthesis of a bioreagent for antibody assays, which will be useful in a test kit
20 for, for example, assaying the presence of enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11.

The present invention is summarized in that a monoclonal antibody specific to enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 is produced by a hybridoma
25 formed by the fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with a "rough" strain of E. coli 0157:H7. This rough strain was modified so that it lacks smooth lipopolysaccharides, which includes expression of 0157 antigen, on its cell
30 surface. The monoclonal antibody is characterized in that it reacts with a protein having a molecular weight of approximately 5,000-6,000 daltons. The protein is a part of the outer membrane proteins of enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11. This protein has
35 apparent specificity for enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11. The monoclonal antibody is further characterized in that it is a member of the

-6-

subclass immunoglobulin G_{2a} and it has a kappa light chain.

5 The present invention is further directed to a method of assaying for the presence of E. coli 0157:H7 in a test sample, comprising the steps of binding polyclonal antibody to E. coli 0157 to adsorptor substrate units to produce antibody to E. coli 0157-charged substrate units, exposing a known quantity of the test material to the antibody E. coli 0157-charged substrate unit so as to
10 cause the antibody to bind to any E. coli 0157:H7 organism present in the test material to produce a reacted unknown sample, exposing a selected quantity of a standard preparation of E. coli 0157:H7 organism having a known amount of E. coli 0157:H7 to the antibody to E. coli 0157-charged substrate unit to create a reacted
15 control sample, exposing the reacted unknown and control samples to a monoclonal antibody (4E8C12) to E. coli 0157:H7 to react with the bound E. coli 0157:H7, removing monoclonal antibody not reacted with the bound E. coli
20 0157:H7 on the antibody to E. coli 0157-charged substrate units and comparatively and quantitatively assaying for the presence of reacted monoclonal antibody on the first and second antibody to E. coli 0157-charged substrate units.

25 The present invention is further directed to a process for producing monoclonal antibodies against enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 comprising propagating a hybridoma formed by fusing a cell capable of producing antibodies against
30 enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 with a myeloma cell and harvesting the antibodies produced by the hybridoma.

 The present invention is also directed to a diagnostic kit for assaying the presence of
35 enterohemorrhagic E. coli 0157:H7 and/or E. coli 026:H11 comprising the monoclonal antibody specific to

-7-

enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 and directions for its use.

The present invention is also directed to a bioreagent for antibody assays comprising a substantially
5 pure protein having a molecular weight of about 5,000-6,000 daltons. The protein is found in the outer membrane of E. coli 0157:H7 or E. coli 026:H11, and is capable of reacting specifically with monoclonal antibodies to E. coli 0157:H7 and E. coli 026:H11.

10 The present invention is also directed to a substantially pure protein found in the outer membrane of E. coli 0157:H7 or E. coli 026:H11 having a molecular weight of about 5,000-6,000 daltons and being capable of reacting specifically with monoclonal antibodies to E.
15 coli 0157:H7 and E. coli 026:H11.

Because of its high specificity, the monoclonal antibody may be a useful reagent for the rapid detection of enterohemorrhagic E. coli 0157:H7 and/or E. coli
20 026:H11 in foods and in clinical specimens. Further, the testing procedure should be reduced to one day or less. The testing procedure would include, first, growing the organism on a selected growth medium and, then, testing for its presence by, for example, enzyme-linked immuno-
25 sorbent assays (hereinafter ELISAs) and other immunoassays.

The present invention is also directed to a specific and sensitive procedure for detecting E. coli 0157:H7 in a substrate such as food. The procedure involves the enrichment of the substrate in a selective
30 enrichment medium containing acriflavin (also spelled acriflavine) to form an enriched culture. The enriched culture is applied to an assay, such as an ELISA assay. In addition to being highly specific and sensitive, the procedure is rapid, easy to perform and is amenable to
35 use by laboratories performing routine microbiological testing. The presumptive positive identification of E. coli 0157:H7 in a substrate can be done in less than 20

-8-

hours. The organism can be isolated and confirmed as E. coli 0157:H7 within 2 days after presumptive positive detection.

5 Other objects and advantages of the invention will be apparent from the following detailed description and figures setting forth the preferred embodiment of the invention.

Brief Description of the Figures

10

Figure 1A is a photograph illustrating the tricine-SDS-PAGE profile of outer membrane proteins (OMP) of E. coli 0157:H7 strain 932 (lane 3), E. coli HA1 (lane 4), E. coli 026:H11 strain 94-381 (lane 5), E. coli 026:H11 strain 89-326, E. coli 0157:H16 (lane 7), and E. coli 0157:H45 (lane 8). A 5 μ g sample of OMP was applied per lane. Low-molecular weight standards (indicated on the left, in thousands) are shown in lanes 1 and 2. The gel was silver stained.

20

Figure 1B is a photograph illustrating a Western blot of SDS-PAGE-separated OMPs treated with MAb 4E8C12. Lane numbers correspond with the OMP preparations indicated in Figure 1A.

25 Figure 2 is a graph illustrating the sensitivity of the monoclonal antibody 4E8C12 in a direct ELISA for detecting E. coli 0157:H7, strain 932, as described in Example II.

30 Figure 3 is a graph illustrating the sensitivity of a sandwich ELISA to detect E. coli 0157:H7 strain 932 in pure culture grown in mTSB with agitation.

Figure 4 is a graph illustrating the effect of growth temperature on detection of E. coli 0157:H7 strain 932 by sandwich ELISA. The cells were grown in mTSB with or without agitation. Legend: \blacktriangle = 37°C with agitation; \triangle = 30°C with agitation; \blacksquare = 37°C static; \square = 30°C static.

35

Figure 5 is a graph illustrating the effect of acriflavin-HCl (10mg/L) and/or casamino acids (10g/L) in

-9-

enrichment medium on enhancement of expression of E. coli 0157:H7 antigens reacting with Mab 4E8C12, as determined by ELISA. Cultures of E. coli 0157:H7 strain 932 were grown at 37°C with agitation. Legend: ○ = mTSB; ■ =
5 mTSB + casamino acids; □ = mTSB + acriflavin-HCl; ● = mTSB + acriflavin-HCl + casamino acids.

Detailed Description of the Preferred Embodiment

10 Enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 have been identified as important human pathogens. They produce one or more toxins (verotoxins) that cause significant intestinal bleeding in several mammals, including humans. The organism is sometimes
15 fatal. It is found in raw milk, raw supermarket meats, etc. and presumably introduced by fecal contamination. Some of the characteristics of E. coli 0157:H7, as described in Ryan et al (supra, 1988), are as follows. E. coli 0157:H7 does not produce heat stable or heat
20 labile enterotoxins. It is not invasive and does not adhere to HeLa cells. It does produce high levels of a Vero cytotoxin that appears to be similar to Shiga toxin. E. coli has been shown to produce one or more different Vero cell cytotoxins, as described in Padhye, Vikas V. et
25 al., 1989, "Production and Characterization of Monoclonal Antibodies to Verotoxins 1 and 2 from Escherichia coli of Serotype 0157:H7," Journal of Medical Microbiology, Vol. 30, pgs. 219-226.

30 E. coli 026:H11 is similar to E. coli 0157:H7 in that both are enterohemorrhagic E. coli that produce verotoxin and cause hemolytic uremic syndrome and hemorrhagic colitis (Bopp, C. A., et al., 1987, "Unusual Verotoxin-Producing Escherichia coli Associated with Hemorrhagic Colitis," J. Clin. Microbiol., Vol. 25, pgs.
35 1486-1489; Karmali, M. A. et al., 1983, "Sporadic Cases of Hemolytic Uremic Syndrome Associated with Fecal Cytotoxin and Cytotoxin Producing Escherichia coli in

-10-

Stools," Lancet, Vol. i, pgs. 619-620; Levine, M. M., supra., 1987).

In general overview, a monoclonal antibody, designated 4E8C12, specific for E. coli 0157:H7 and E. coli 026:H11 was produced by immunizing BALB/c mice with a "rough" strain of E. coli 0157:H7 deficient of the 0157 antigen. Spleen cells from the mice so immunized were fused with a mouse myeloma cell, with the fusion being effected with treatment in polyethylene glycol in accord with known methods. The resulting hybridomas were cultured and then selected for antibody activity. The cells producing antibodies specific to E. coli 0157:H7 and E. coli 026:H11 were detected by means of an ELISA, in the manner well known to the art. The antibody was purified from ascites fluid in conventional ways. The cloned cell line so created and selected was perpetuated by conventional cell culturing techniques.

The hybridoma produced in this manner was deposited at the American Type Culture Collection on May 10, 1990, and has been assigned the designation HB 10452. This particular hybridoma and the antibodies produced thereby are the hybridoma and monoclonal antibodies referred to below, unless otherwise stated. A detailed description of the making of the hybridoma is included below. Future reference to the hybridoma is as follows: ATCC HB 10452.

This deposit is made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organism will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between applicants and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of the pertinent U.S. patent or upon laying

-11-

open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto including 37 CFR § 1.14 with particular reference to 886 OG 638). The assignee of the present application agrees that if the culture on deposit should die or be lost or destroyed when cultivated under suitable conditions, it will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

In contrast with previously reported references, which disclose monoclonal antibodies that react with E. coli 0157:H7 but also bind to the somatic 0157 antigen and hence react with all E. coli belonging to the serogroup 0157 (Perry, M. B. et al., 1988, "Identification of Escherichia coli Serotype 0157 Strains by Using a Monoclonal Antibody," J. Clin. Microbiol., Vol 27, pgs. 1973-1978), the monoclonal antibody of the present invention does not react with the 0157 antigen and is, with the exception of one other serotype of E. coli, very specific for E. coli 0157:H7. The other serotype is E. coli 026:H11. As used herein, the phrase "specific for E. coli 0157:H11 and E. coli 026:H11" is intended to mean that the monoclonal antibody of the present invention does not react with the strains of E. coli listed on Table 2 in Example 1, infra.

The antibodies were tested for specificity by ELISAs and by immunoblotting of a variety of enterics. By these means, it was determined that the monoclonal antibody forms a strong reaction by direct ELISA with each of 36 strains of E. coli 0157:H7 and 5 strains of E. coli 026:H11. However, there was no cross-reactivity

-12-

with strains of other enterics such as, for example, Salmonella, Yersinia enterocolitica, Shigella, Proteus, Klebsiella, Campylobacter jejuni, Serratia, Aeromonas hydrophila, Citrobacter, Enterobacter, Hafnia, Escherichia hermannii, and all other strains of E. coli other than the serotypes 0157:H7 and 026:H11 (including strains of serotype 0157 but not H7).

Studies on the monoclonal antibody to E. coli 0157:H7 and 026:H11 show that the monoclonal antibody (Mab) has the following characteristics: (1) it is a member of the subclass IgG_{2a}; (2) it has a kappa light chain; and (3) it reacts specifically with an outer membrane protein of enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 having a molecular weight of approximately 5,000-6,000 daltons, as determined by SDS-polyacrylamide gel electrophoresis of outer membrane proteins of E. coli of different serotypes followed by Western blot analysis.

Originally, the outer membrane protein of enterohemorrhagic E. coli 0157:H7 and E. coli 026:H11 was believed to have a molecular weight of about 13,000 daltons. The molecular weight determination was made using a 15% sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) system to resolve the protein. The protein appeared as a doublet, i. e., two closely related bands. The doublet was believed to represent one protein in the outer membrane of the microorganisms having a molecular weight of approximately 13,000 daltons.

Evidence now indicates that the aforementioned system was not efficient to resolve low molecular weight proteins (Padhye, N.V. and M. P. Doyle, Jan. 1991, J. Clin. Microb., 29(1):99-103). The outer membrane protein most likely has an apparent molecular weight of approximately 5,000 - 6,000 daltons. The cellular component of E. coli 0157:H7 and 026:H11 that reacted with Mab 4E8C12 was determined by tricine-SDS-PAGE

-13-

(Schagger, H. and G. Jagow, 1987, Anal. Biochem. 166: 368-379) followed by Western immunoblot analysis.

5 The outer membrane proteins (OMP) from E. coli 0157:H7 strain 932, E. coli HA1, E. coli 0157:H16, E. coli 0157:H45 and E. coli 026:H11 were separated by a special tricine-SDS-PAGE procedure because of the necessity to separate low-molecular weight proteins with high resolution. Reference is made to Fig. 1A. The separated proteins from a second gel were transferred to a polyvinyl difluoride membrane, and the location of antigen recognized by Mab 4E8C12 was determined by Western blot analysis. The Mab reacted with two 5,000-6,000 molecular weight OMP's of E. coli 0157:H7 strain 932, E. coli HA1 and E. coli 026:H11 as illustrated in Fig. 1B. No cross-reaction was observed with either E. coli 0157:H16 or E. coli 0145:H45.

10 The determination of molecular weight was confirmed by additional tests on the amino acid compositions of the bands. The amino acid compositions of both the bands as well as the purified protein (purified using high performance liquid chromatography or HPLC) were nearly identical with only some slight variation as illustrated below in Table 1.

-14-

Table 1

Amino Acid Composition of Targeted Outer Membrane Protein

| 5 | Amino Acid | No. of residues based on 50 amino acids | | |
|----|---------------|---|------------|--------------------|
| | | Lower Band | Upper Band | Protein after HPLC |
| 10 | Aspartic Acid | 4 | 5 | 4 |
| | Threonine | 2 | 3 | 2 |
| | Serine | 4 | 6 | 6 |
| 15 | Proline | 2 | 2 | 1 |
| | Glycine | 10 | 10 | 9 |
| 20 | Alanine | 4 | 5 | 4 |
| | Methionine | 1 | 1 | 1 |
| | Isoleucine | 2 | 2 | 2 |
| 25 | Leucine | 4 | 5 | 4 |
| | Tyrosine | 1 | 1 | 1 |
| 30 | Phenylalanine | 2 | 2 | 2 |
| | Histidine | 1 | 1 | 1 |
| | Lysine | 2 | 2 | 2 |
| 35 | Arginine | 2 | 2 | 2 |
| | Glutamic Acid | 7 | 6 | 6 |

40

A certain percentage of discrepancy is expected because upon hydrolysis some amino acids are oxidized to variable extents yielding different numbers of residues each time. However, the number of stable amino acids such as tyrosine, phenylalanine, histidine, lysine and arginine is constant in all the three proteins.

45

Thus, it is believed that the targeted outer membrane protein is at least one protein having an apparent molecular weight of approximately 5,000 - 6,000.

50

Aside from the amino acid composition of the outer

-15-

membrane protein(s), other evidence which supports that the outer membrane protein is one protein having a molecular weight of approximately 5,000 - 6,000 includes a common isoelectric point; common epitopes on both the protein bands recognized by the monoclonal antibody 4E8C12, and a single peak disclosed after HPLC purification.

ELISAs are a conventional method for assaying for the presence of an antigen in a sample of test material. The sandwich ELISA of the invention is adapted to assay for the presence of enterohemorrhagic E. coli 0157:H7 in a sample of test material and includes the following steps. First, a known antibody to E. coli 0157 is bound to a suitable adsorptor substrate. Preferably, a plastic culture plate is used, such as a 96-well polystyrene culture plate (Costar, Cambridge, Mass. - Model No. 3596). A solution of antibody to E. coli 0157 is placed in each of the wells and allowed to remain under conditions such that the antibody to E. coli 0157 is adsorbed to the surface of the wells. Unabsorbed antibody solution is then washed away, leaving the antibody to E. coli 0157 bound to the adsorptive walls of the wells, which shall be referred to as "adsorptor substrate units." With antibody to E. coli 0157 adsorbed to them, they shall be referred to as "antibody to E. coli 0157-charged substrate units." The antibody to E. coli 0157-charged substrate units is then treated with an appropriate blocking reagent, such as nonfat dried milk, to block non-specific binding sites. After appropriate incubation, this reagent is removed.

Next, a known quantity of the test material is exposed to the antibody to E. coli 0157-charged substrate units for an appropriate period of time, and then is removed by washing. Any E. coli 0157:H7 in the test material will bind to the antibody to E. coli-charged substrate units.

-16-

Similarly, a standard preparation of E. coli 0157:H7 is exposed to another set of antibody to E. coli 0157-charged substrate units to serve as a control.

5 The monoclonal antibody referred to above is added to the antibody to E. coli 0157-charged substrate units to bind with any bound E. coli 0157:H7. After appropriate incubation, unbound the monoclonal antibody is removed by washing.

10 The antibody to E. coli 0157-charged substrate units reacted with test samples or E. coli 0157:H7 are then assayed for the presence of monoclonal antibody.

15 Preferably this is done by exposing antibody to E. coli 0157-charged substrate units reacted with the test samples or E. coli 0157:H7 and the monoclonal antibody thereon to a marker-coupled anti-mouse antibody to allow the marker-coupled antibody to bind to any monoclonal antibody present. The unbound marker-coupled antibody is then removed, and the amount of marker remaining on the antibody to E. coli 0157-charged
20 substrate units is measured. The marker may be an enzyme measured by its effect on a selected reagent, a fluorescent material, a radioactive material, or any other of the markers familiar to one skilled in the art. It will be apparent that the monoclonal antibody itself
25 may be combined directly with a marker, whereupon the step of reacting a marker-coupled anti-mouse antibody may be omitted.

The monoclonal antibody may also be used in other conventional ELISAs. For example, a sample of test
30 material may be bound to an adsorbtor substrate and then exposed to the monoclonal antibody disclosed above. The antibody binds to any E. coli 0157:H7 or E. coli 026:H11 present in the test material. Unbound portions of the monoclonal antibody are then removed. Next, an assay
35 comparable to those discussed above is conducted for the presence of bound monoclonal antibody.

-17-

The monoclonal antibody of the present invention may also be used in any of the generally known methods of using such antibodies in immunohistological techniques for examining a substantially cohesive, nonfluid test material, such as a cell or tissue sample. Preferably, the sample is a food product or a fecal sample. The test material is incubated with the monoclonal antibody to bind the antibody to E. coli 0157:H7 or E. coli 026:H11 present in the test material. The test material is then washed to remove the unbound portion of the monoclonal antibody. The antibody may then be reacted in such a way as to make its presence visually apparent. Typically, the test material bearing monoclonal antibody bound to E. coli 0157:H7 or E. coli 026:H11 contained therein is incubated with a marker-labeled anti-mouse antibody comparable to those discussed above. The marker-labeled antibody binds to the monoclonal antibody. A marker is selected such that it may be made visually apparent. Fluorescent and enzyme markers typically are used. The test material is then microscopically observed under conditions adapted to render the marker visually perceivable. The monoclonal antibody to E. coli 0157:H7 and E. coli 026:H11 is specifically useful as a reagent for the rapid detection of E. coli 0157:H7 and/or E. coli 026:H11 in food and clinical specimens.

The method for assaying the presence of an antigen in a test material can be enhanced by using a selective enrichment medium to enrich the test material prior to assay. The enrichment medium is a modified trypticase soy broth (MTSB), formulated by Doyle and Schoeni (supra, 1987), which has been further modified to include acriflavin-Hcl and casamino acids. We found the both acriflavin-Hcl and casamino acids substantially enhances antigen expression by E. coli 0157:H7. In addition, casamino acids enhance the growth of E. coli 0157:H7, and acriflavin-Hcl inhibits the growth of gram-

-18-

positive bacteria. Although the exact mechanism by which acriflavin-HCl enhances the antigen expression by E. coli 0157:H7 is not known, it is believed that it may be a consequence of the suppression of the formation of the cell wall lipopolysaccharide so that the antigen recognized by the monoclonal antibody is better expressed.

Although a variety of assay techniques as described above may be used to accommodate the enrichment medium, a preferred assay technique is the sandwich ELISA procedure known to the art. For the purposes of this patent application, the herein described assay technique will be designated the "enrichment-sandwich ELISA procedure." The procedure involves enrichment of a test sample or substrate such as food in a selective enrichment medium for approximately 16-18 hours at 37°C with agitation (150 rpm). The enrichment culture is applied to a sandwich-ELISA that has a polyclonal antibody specific for the E. coli 0157:H7 antigen as the capture antibody and a monoclonal antibody specific for enterohemorrhagic E. coli of serotypes 0157:H7 and 026:H11 as the detection antibody. The ELISA can be completed within 3 hours.

The enrichment-sandwich ELISA procedure for detection of E. coli 0157:H7 described herein is rapid, sensitive and easy to perform. The procedure can detect as few as 0.2 E. coli 0157:H7/g of ground beef. E. coli 0157:H7 can be detected in less than 20 hours (h), including enrichment. Hence, this procedure can be very useful for routine screening of food samples.

The present invention also includes kits, e.g., diagnostic assay kits, for utilizing the monoclonal antibody to E. coli 0157:H7 and E. coli 026:H11 and carrying out the method disclosed above. In one embodiment, the diagnostic kit would conventionally include the monoclonal antibody to the E. coli 0157:H7 and E. coli 026:H11 in one or more containers, a

-19-

conjugate of a specific binding partner for the monoclonal antibody, a label capable of producing a detectable signal, and directions for its use. The kit may be conjugated to a label, as is well known to the art. Various labels include enzymes, radioisotopes, particulate labels, chromogens, fluorescers, chemiluminescers, coenzymes, free radicals, and bacteriophages. Additionally the monoclonal antibody may be bound to a support.

A specific diagnostic kit could be in a dipstick format. This could involve adsorbing polyclonal E. coli 0157 immunoglobulin to a hydrophobic polyvinylidene difluoride (PVDF)-based membrane. The PVDF membrane is then treated with 5% bovine serum albumin to block nonspecific binding sites. The PVDF membrane is dipped for 30 minutes in an enrichment culture of food that may contain E. coli 0157:H7. After washing, the PVDF membrane is treated with monoclonal antibody 4E8C12. This antibody will bind to any E. coli 0157:H7 cells bound to the PVDF membrane. The bound monoclonal antibody 4E8C12 is detected with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin that reacts with Nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate substrate to produce purple spots as a positive reaction.

The approximately 5,000-6,000 dalton molecular weight protein found in the outer membrane of E. coli 0157:H7 and E. coli 026:H11 can also be isolated as a bioreagent and used to prepare monoclonal antibodies for detection of E. coli 0157:H7 and E. coli 026:H11 in a sample. The monoclonal antibodies can be provided in test kits which are used to diagnose cases of suspected E. coli 0157:H7 and E. coli 026:H11 contamination.

The examples below provide specific examples of the invention disclosed herein.

-20-

EXAMPLE IPreparation of the Cloned Cell Line

Bacterial Strains: Bacterial cultures used to identify specificity of monoclonal antibody: The following strains of bacteria were studied in these examples: E. coli 0157:H7 strain 932; E. coli HA1 (a rough strain derived from E. coli 0157:H7 932), thirty-four other strains of E. coli 0157:H7, as listed in the following Table 2, five strains of E. coli 026:H11, and thirty-seven strains of E. coli other than 0157:H7 or 026:H11, as listed in the following Table 2:

-21-

TABLE 2E. coli Serotype 0157:H7Strain No.

932
1083-83
CL-8
1215-83
CL-40
936-86
204-P
W2-2
EC-13
100B
RPS 386-1
EC-12
SL-19808
1091-83
A8187 M3
EC-14
1093-83
SL-20069
NX 0157:H7
1095-83
202-P
RPS-779
749-83
HA1
2790
28890
85-1
85-7
86-1
86-7
87-3
87-18
30898-1 MUG
933
505-B
301-C

-22-

TABLE 2 CONT.E. coli other than serotype 0157:H7Strain No.

929-78
C-600 933W
933-J
EC PB40
EC GV50B
EC PB-200
EC PB-175
K88
K99
RSF 1030
E. coli R1
RP4
E. coli K-12
88-1947 (0157:H16)
A2 (0157:H19)
84-1097 (0157:H25)
624-83 (0157:H45)
OPHD (0157:H-)
88-573 (02:H7)
88-766 (018:H7)
CL-15 (0113:H21)
CL-37 (0111:H8)
497-18 (028ac:NM)
0128:B12
3288-85 (0172:NM)
3056-85 (050:H7)
3030-86 (011:NM)
3377-85 (04:NM)
3153-86 (0125:NM)
75-83 (0145:NM)
A96119-C2 (045:H2)
3143-85 (05:NM)
3007-85 (0111:NM)
88-573 (026:H11)
84-381 (026:H11)
105B
A-2028
CL-5 (026:H11)
89-386 (026:H11)
3047-86 (026:H11)

-23-

TABLE 2 CONT.Bacterial Strains Studied (cont'd.)

| | <u>Strain No.</u> |
|-------------------------------|--|
| <u>Shigella dysenteriae</u> | 4386 6611 |
| <u>Escherichia hermanii</u> | 89-201 |
| <u>Proteus mirabilis</u> | SLH 16606 MC-3 |
| <u>Proteus vulgaricus</u> | 8068 |
| <u>Serratia marcescens</u> | 23521 |
| <u>Salmonella infantis</u> | 1-2 5 6S |
| <u>Salmonella urbana</u> | 9261 |
| <u>Salmonella enteritidis</u> | 11013 |
| <u>Salmonella typhimurium</u> | S-7 S-9 S-12 S-15 E 1297 S-14 S-18 S-19 E-40 9840 |
| <u>Campylobacter jejuni</u> | FRI 209 FRI 205 FRI 145 74C C122 |

-24-

TABLE 2 CONT.Bacterial Strains Studied (cont'd.)

| | <u>Strain No.</u> |
|---------------------------------|---|
| <u>Klebsiella pneumoniae</u> | 272-6 F182-5(1) F182-5(2) F182-6(1) F184-5(4) F184-5(5) F184-6(1) F188-5(4) F189-5(2) F189-5(3) F189-6(1) F190-6(3) F190-7(5) |
| <u>Klebsiella oxytoca</u> | 11696 |
| <u>Citrobacter freundii</u> | Y6 ₁ 10RS A2 ₄ 4R1 8027 JF1 |
| <u>Citrobacter amalancticus</u> | 28422 |
| <u>Citrobacter freundii</u> | MAT-8 6 |
| <u>Citrobacter diversus</u> | MA ₁ S-9 MA ₄ S-9 275-6 LMH 5 274-8 |

-25-

TABLE 2 CONT.Bacterial Strains Studied (cont'd.)

| | <u>Strain No.</u> |
|--------------------------------|--|
| <u>Versinia enterocolitica</u> | IP-183 IP-162 2635-NT 34 30118 705 675 PT-120 Y-7P PT-63 736 WA |
| <u>Enterobacter cloacae</u> | 274-6 272-6 |
| <u>Hafnia alvei</u> | CB-7 |
| <u>Aeromonas hydrophila</u> | 7 12 17 23 |

-26-

All bacteria were grown in TRYPTICASE® Soy Broth (TSB) (BBL Microbiology Systems, Cockeysville, MD) at 37°C for 16-18 hours with agitation (100 rpm).

5 **Toxins:** Verotoxins-1 (VT-1) and Verotoxin-2 (VT-2) from E. coli 0157:H7 strain 932 were purified according to the procedures described by Padhye et al. (supra).

10 **Preparation of antigen for inoculation:** E. coli HA1 cells were grown in TSB at 37°C for 16 hours with agitation (100 rpm). The cells were harvested by centrifugation (3500 rpm for 10 minutes) and were washed 3 times with 0.01M phosphate buffered saline (pH 7.2). E. coli HA1 cells were treated with 2% Formalin and held at 37°C for 1 week.

15 Ten BALB/c mice (males, 6-8 weeks old) were immunized by intraperitoneal injection of 2×10^8 cells of Formalin-treated E. coli HA1. Thereafter, every 4 weeks the mice received intraperitoneally the same number of Formalin-treated cells of E. coli HA1 until sera obtained by periodic bleeding of mice had titers greater than 1:400. This generally required 3 inoculations. Four days before cell fusion, the mice were given a final intravenous booster injection of 1×10^8 Formalin-treated cells of E. coli HA1. Four to five months after the
20 initial injection, mice were sacrificed and their spleen cells were fused with myeloma cells.

25 **Fusion and cloning:** The fusion and cloning process was performed according to the procedure of Galfre, G., 1981, "Preparation of Monoclonal Antibodies: Strategies and Procedures," Methods in Enzymology, Vol. 73, pgs. 1-46.) with minor modifications. Briefly, spleen cells from the immunized mice were fused with Sp2/0-Ag-14 myeloma cells using 40% polyethylene glycol (Molecular weight, 1300-1600) (J.T. Baker Chemical Co.,
30 Phillipsburg, NJ) and were grown in selective media containing hypoxanthine, aminopterin, and thymidine (HAT) with 0.3% mouse red blood cells. Supernatant
35

-27-

fluids from wells with hybridoma growth were screened for the production of antibodies against E. coli 0157:H7 by direct ELISA as described below. Hybridomas of interest were sub-cloned twice by the method of Kohler & Milstein (1975) Nature, Vol. 256, pgs. 495-497, by limiting dilution at 0.5 and 0.1 cell/well in a media containing 20% fetal bovine serum (Gibco, Grand Island, NY) and reassayed for antibody production.

5
10
15
20
25
30
35

Direct ELISA: Antibody production was determined by ELISA performed in a 96-well styrene EIA-RIA plate (Gibco, Grand Island, NY). Each well was coated with 100 microliters (μ l) of bacterial cells (E. coli 0157:H7 strain 932, E. coli 0157:H16, E. coli 02:K1:H7, or E. coli K-12 (negative control) or 10^7 cells, optical density of 0.5 at 640 nm) in 50 mM carbonate buffer, pH 9.6, and rotated overnight on an orbital shaker at room temperature. After washing the cells 4 times with 50 mM tris-HCl, pH 7.5, plus 150 mM NaCl (TBS), the remaining binding sites were blocked with 5% BSA in TBS. After 1 hour of incubation at 37°C, the blocking buffer was removed and 100 μ l of monoclonal antibody (hybridoma supernatant fluid) was added to the wells. The plates were incubated at 37°C for 1 hour and then the wells were washed 4 times with TBS plus 0.05% Tween-20 (TBS-T). Horseradish peroxidase-conjugated goat anti-mouse IgG (100 μ l/well; 1:1400 in TBS) (Kirkegaard & Perry Laboratory, Inc. Gaithersburg, MD) was added and incubated at 37°C for 1 hour. After washing the wells 4 times with TBS-T, 100 μ l of ABTS-peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added per well. The enzymatic reaction was stopped with 50 μ l of 1% sodium dodecyl sulfate (SDS) in TBS per well after 15 minutes incubation at room temperature. The optical density of reactants in each well was measured by a Dynatech (MR300) microplate reader at 410 nm. Reproducibility of the assay was determined by duplicate testing.

-28-

Ascitic fluid: Ten BALB/c mice were primed by intraperitoneal injection of 0.5 ml of 2, 6, 10, 14-tetramethyl pentadecane (Pristane) (Sigma Chemical Co., St. Louis, MO). Ten days later mice were injected with 2×10^6 hybridoma cells. Mouse ascitic fluid was collected from 10 through 20 days after injection. Cell debris and fibrin clots were removed by centrifugation (8000 xg at 10 minutes) and antibody containing fluids were stored at -20°C.

Purification of monoclonal antibodies: The monoclonal antibody from the ascitic fluid was purified according to a modification of the manufacturer's instructions using a protein A column (Immunopure plus IgG purification kit, Pierce, Rockford, IL). Briefly, ascitic fluid was centrifuged at 10,000 xg for 20 minutes and IgG-binding buffer was added (3:1) to the supernatant fluid. This solution (4 ml) was applied to the column and the monoclonal antibody was eluted with IgG-elution buffer. One-ml fractions were collected and protein levels were monitored by measuring (optical density at 280 nm). Fractions with proteins were combined and were dialyzed against 20 mM phosphate buffer, pH 7.0, overnight at 4°C. Finally, the protein concentration was determined according to the procedure described by Smith et al., 1985, "Measurement of Protein Using Bicinchoninic Acid," Analytical Biochemistry, Vol. 150, pgs. 76-85, using Pierce BCA protein reagent (Pierce Chemical Co., Rockford, IL) and bovine serum albumin as a standard. The activity of purified antibody was determined by SDS-PAGE. direct ELISA and purity was determined by immunoglobulin

Immunoglobulin isotyping: Immunoglobulin isotyping was done by ELISA using class specific antisera. Wells of EIA plates were coated with E. coli 0157:H7 strain 932 (10^7 cells/ml) in 50mM carbonate buffer (pH 9.6). After 4 washes with TBS, nonspecific binding sites were blocked with 5% bovine serum albumin in TBS (W/V). After 1 hour incubation at 37°C, 0.1 ml of

SUBSTITUTE SHEET

-29-

the supernatant containing monoclonal antibody 4E8C12 was added to each well and incubation was continued for an additional hour at 37°C. After washing the wells 4 times with TBS-T, rabbit antisera specific individually for mouse IgG, IgG_{2a}, IgG_{2b}, IgG₃, IgM, IgA, kappa or lambda light chains (Mouse-types Isotyping kit, Bio-Rad Laboratories, Richmond, CA) were added and held at 37°C for one hour. The wells were washed 4 times with TBS-T and alkaline phosphatase-labeled goat anti-rabbit IgG (0.1 ml; diluted 1:800 in TBS) was added to each well followed by incubation at 37°C for 1 hour. After washing the wells 4 times with TBS-T, phosphatase substrate (p-nitrophenylphosphate) (1.0 mg/ml) in 1.0M 2 amino-2 methyl-1-propanol, pH 9.9, was added and an optical density at 410 nm was determined after 1 hour incubation at 37°C.

Preparation of outer-membrane proteins: Outer membrane proteins (OMP) were isolated according to the method described by Hancock and Naikaido (Hancock, R.E.W. and H. Naikaido, 1987, "Outer Membranes of Gram-Negative Bacteria," Journal of Bacteriology, Vol. 36, pgs. 381-390.), with minor modifications. E. coli 0157:H7 strain 932, E. coli HA1, E. coli 0157:H16, E. coli 0157:H45, and E. coli CL-5 026:K-60:H11 were grown individually in 2 liters of TSB at 37°C for 18 hours with agitation (150 rpm). Cells were harvested by centrifugation (10,000 xg for 10 minutes at 4°C) and subsequent operations were performed at 4°C. Cells were washed with 0.01 M phosphate buffer, pH 7.2, containing 170 mM NaCl (PBS), sedimented by centrifugation, and the pellets were resuspended in the same buffer to a calculated optical density of 40 at 640 nm. Cells were broken in a French Press (1400 lb/in²) (American Instrument Company, Silver Spring, MD) and cell debris was removed by centrifugation (5000 xg for five minutes). OMP were sedimented from the supernatant fluid by centrifugation at 200,000 xg for 1 hour. Pellets were resuspended in 0.01 M HEPES (N-2

SUBSTITUTE SHEET

-30-

hydroxyethyl piperazine-N'-2 ethane sulfonic acid) buffer, pH 7.4, at an approximate protein concentration of 20 mg/ml. The protein solutions were layered on a 35-55% (W/V) sucrose gradient prepared in 0.01 M HEPES
5 buffer and OMP were pelleted by centrifugation at 131,000 xg for thirty-six hours. The OMP were resuspended in 0.01 M HEPES buffer containing 1 mM MgCl₂ and sedimented by centrifugation (200,000 xg for 1 hour). Pellets were resuspended in the same buffer and stored at -20°C.
10 Protein concentrations were measured according to the procedure described above.

Immunoblotting: OMP (50 ug) and purified VT-1 and VT-2 (3-5 ug) were separated into individual protein bands by sodium dodecyl sulfate (SDS) - polyacrylamide
15 gel electrophoresis. The gels were run in a double slab electrophoresis cell (Protean, Bio-Rad Laboratories, Richmond, CA) at a constant voltage of 200V until bromophenol dye reached 1 cm from the bottom of the gel. After electrophoresis, protein bands were transferred to
20 a PVDF membrane (IMMOBILIM™, Millipore, Bedford, MA) in a buffer containing 25 mM Tris, 192 mM glycine and 20% methanol (W/V) using a transblot apparatus (Bio-Rad Laboratories, Richmond, VA) at 30V for 18 hours. The membrane was stained immunochemically as follows.
25 Nonspecific binding sites were blocked by incubation with 5% BSA in TBS for 1 hour at 37°C. After rinsing the gel with 1% BSA in TBS, the PVDF membrane was incubated with monoclonal antibody 4E8C12 (Ascites fluid diluted 1:6000 in TBS) for 1 hour at 37°C. The membrane was washed 3
30 times with TBS plus 0.05% Tween-20 (TBS-T) and was incubated with alkaline phosphatase-labeled goat-anti-mouse (IgG diluted 1:2000 in TBS) for 30 minutes at 37°C. The membrane was washed thoroughly with TBS-T [+0.05% SDS] and treated with BCIP/NBT phosphatase substrate
35 (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) to detect protein bands. Low molecular weight standards (Electrophoresis Calibration Kit, Pharmacia, Piscataway,

-31-

NJ) were run on each gel and each was stained with 0.25% Commassie brilliant blue R-250 (Imperial Chemical, London) before and after transfer, to document the transfer of proteins.

5

EXAMPLE II

Determination of Sensitivity of the Monoclonal Antibody

The sensitivity of the monoclonal antibody was determined using a direct ELISA with various levels of 8 different strains of E. coli 0157:H7. The detection limit was in the range of 10^4 to 10^5 cells/ml. An example is shown in Fig. 2 which illustrates the sensitivity of monoclonal antibody 4E8C12 in a direct ELISA for detecting E. coli 0157:H7, strain 932.

15

EXAMPLE III

Specificity of the Monoclonal Antibody

The specificity of the monoclonal antibody was determined by examining the cross-reactivity with different enteric bacteria. The following bacteria listed in Table 2 of Example I were tested according to the procedures of Example I. The results are presented below in Table 2.

20
25

-32-

TABLE 2

Reactivity of MAb 4E8C12 with E. coli 0157:H7
and Other Enteric Bacteria

| Organism Positive ^a | No. of Strains Tested | No. |
|---|-----------------------|-----|
| <u>Escherichia coli</u> | | |
| 0157:H7 | 36 | 36 |
| 0157:H16 | 1 | 0 |
| 0157:H19 | 1 | 0 |
| 0157:H25 | 1 | 0 |
| 0157:H45 | 1 | 0 |
| 0157:H ⁻ | 1 | 0 |
| 02:K1:H7 | 1 | 0 |
| 026:H11 | 5 | 5 |
| 028ac | 1 | 0 |
| 0111 | 3 | 0 |
| 0113 | 1 | 0 |
| 0124 | 1 | 0 |
| 0128 | 1 | 0 |
| Additional serotypes other than 0157:H7 or 026:H11 | 23 | 0 |
| <u>Escherichia hermanii</u> | 1 | 0 |
| <u>Proteus</u> spp. | 3 | 0 |
| <u>Klebsiella pneumoniae</u> | 13 | 0 |
| <u>Klebsiella oxytoca</u> | 1 | 0 |
| <u>Cytrobacter</u> spp. | 11 | 0 |
| <u>Serratia marcescens</u> | 1 | 0 |
| <u>Shigella dysenteriae</u> | 2 | 0 |
| <u>Salmonella</u> spp. | 17 | 0 |
| <u>Campylobacter jejuni</u> | 5 | 0 |
| <u>Yersinia enterocolitica</u> | 12 | 0 |
| <u>Enterobacter cloacae</u> | 2 | 0 |
| <u>Hafnia alvei</u> | 1 | 0 |
| <u>Aeromonas hydrophila</u> | 4 | 0 |

^aOD₄₁₀ value of 0.2 above background was considered positive; all positive strains had OD values >1.0 above background.

^bE. coli 026:H11 were isolated from patients with hemolytic uremic syndrome or hemorrhagic colitis.

-33-

Discussion of Results: The MAb was highly reactive with all 36 strains of E. coli 0157:H7 as determined by ELISA, with an O.D. of >1.0 for all strains tested. The specificity of Mab 4E8C12 was determined by ELISA using E. coli strains other than serotype 0157:H7 and several strains of Y. enterocolitica, Salmonella spp., Enterobacter cloacae, C. jejuni, S. dysenteriae, Proteus spp., A. hydrophila, Hafnia alvei, K. pneumoniae, K. oxytoca, S. marcescens and Citrobacter spp. Five strains other than serotype 0157:H7, i.e., all E. coli 026:H11, reacted with the Mab (Table 2). These strains were isolated from patients with hemolytic uremic syndrome or hemorrhagic colitis and produce verotoxin identical to that produced by E. coli 0157:H7.

From the examples disclosed, one skilled in the art will appreciate that the monoclonal antibody disclosed above may be utilized in a variety of ways with respect to the antigen for which it has been shown to be specific. Thus, it may be used to assay E. coli 0157:H7 and 026:H11 in other ELISAs than sandwich ELISAs of the sort disclosed. It may be used as well in other conventional methods for utilizing an antibody for assay and other purposes, whether by utilization of immunofluorescence, immunoperoxidase reactions, or other such techniques.

EXAMPLE IV

DEVELOPMENT OF A RAPID AND SENSITIVE METHOD

TO DETECT AND ISOLATE E. COLI 0157:H7

Bacterial strains: E. coli 0157:H7 strains 933, 505B, 932, CL-8 and 32381 were used for inoculation studies to determine the sensitivity of the enrichment-ELISA procedure. Strains 933 and 505B were isolated from beef, whereas strains 932, CL-8, and 32381 were human isolates. These plus twenty other strains of E. coli 0157:H7, E. coli of serotypes 0157:H16, 0157:H19, 0157:H25, 0157:H45, and E. coli K-12, were used for evaluation of the ELISA procedure only.

-34-

Monoclonal antibody production: Ascitic fluid of monoclonal antibody 4E8C12 IgG2a, specific for enterohemorrhagic E. coli O157:H7 and O26:H11, was obtained from BALB/c mice injected with 10^6 hybridoma (4E8C12) cells.

Ascitic fluid was stored at -20°C until used.

Enhancement of expression by E. coli O157:H7 of antigens recognized by MAb 4E8C12: E. coli O157:H7

strain 932 was grown in modified Trypticase soy broth (mTSB); comprised of (per liter) Trypticase soy broth (TSB; 30 g) [BBL Microbiology Systems, Cockeysville, Md.], bile salts No. 3 (1.5 g), K_2HPO_4 (1.5 g) and novobiocin (20 mg) with agitation (150 rpm) at 37°C for 16 h. Several different growth factors were added

individually or in combination to mTSB to increase the sensitivity of the ELISA. The growth factors evaluated included 1% glucose, rhamnose, mannose, lactose or sucrose, iron supplements such as 0.5-5% sheep red blood cells, 5-50 mg FeCl_3/L , 0.5 FeSO_4/L or 50 mg

$\text{Fe}(\text{NH}_4)_2(\text{SO}_4)_2/\text{L}$, cation chelators such as 5 g Chelex 100/L (Biorad, Richmond, CA) or 0.01 and 0.05% EDTA, 0.5, 2, 5, 8 and 10 mg acriflavin-HCl/L, and 0.5 and 1% casamino acids. In addition, different growth media such as TSB, mTSB and antibiotic medium no. 3 (PAB) and

different growth temperatures (30°C , 37°C and 42°C) with or without agitation (150 rpm) were evaluated. Following growth, cells were sedimented by centrifugation ($1500 \times \text{g}$, 10 min) then

resuspended in 50 mM carbonate buffer, pH 9.6, and

adjusted to an optical density (OD) of 640 of 0.5 (ca. 10^8 cells/ml). The cell suspension was serially (1:10) diluted in carbonate buffer to ca. 10^4 cells/ml, and 100 μl of each serial dilution was applied in duplicate to

wells of 96-well polystyrene EIA-RIA plates (GIBCO, Grand Island, N.Y.). These cell preparations were used in a

direct ELISA procedure to determine the extent of expression of the E. coli O157:H7 antigens reacting with

-35-

MAb 4E8C12. Higher expression of the antigen resulted in a lower detection limit of the ELISA (higher sensitivity). All experiments were replicated twice.

Media preparation: The enrichment medium, mTSB without novobiocin (dmTSB) plus casamino acids (10 g/L) and acriflavin-HCl (10 mg/L) (dmTSB-CA), was prepared by first autoclaving dmTSB plus casamino acids at 121°C for 15 min. This was allowed to cool to room temperature, then an aqueous solution of filter-sterilized acriflavin-HCl was added. For enrichment of E. coli O157:H7 in dairy products, dmTSB-CA with buffer consisting of 1.35 g KH₂PO₄ and 12g Na₂HPO₄ per L (dmTSB-CA-buf) was used instead of 1.5 g K₂HPO₄ per L.

MacConkey-sorbitol agar (Difco Laboratories, Detroit, Mich.) with 4-methylumbelliferone β -D-glucuronide (0.1 g/L) (MSA-MUG) was used for isolation of E. coli O157:H7 from enrichment culture.

Inoculation studies: Fresh retail ground beef, raw milk, pasteurized whole and skim milk, and Cheddar, Swiss, Colby and brick cheese were inoculated with different levels of E. coli O157:H7 to determine the sensitivity of the detection procedure. Aerobic plate counts were done on each product before inoculation using plate count agar and incubating plates at 30°C for 48 h. Inocula of E. coli O157:H7 were prepared by growing individually the five strains for 16 h at 37°C in TSB. Cells were sedimented by centrifugation 1500 x g for 10 min and resuspended in 0.01 M phosphate buffered saline, pH 7.2, (PBS) to an OD₆₄₀ of 0.5 (ca. 10⁸css CFU/ml). Cells were diluted appropriately in PBS to obtain 5 to 22.5 E. coli O157:H7 per 300 μ l which was inoculated into 25g of product. Actual inoculum levels were determined by culturing dilutions of inocula on TSA plates at 37°C for 16 h. Each strain of E. coli O157:H7 was tested individually. Uninoculated samples of each product were included in each study as a control.

-36-

Ground beef samples (25 g each) were added individually to 225 ml of dmTSB-CA broth in 1-L Erlenmeyer flasks, and dairy products (25 g each) were added to 225 ml of dmTSB-CA-buf for enrichment of E. coli 0157:H7. All samples were incubated at 37°C for 16-18 h with agitation (150 rpm). After incubation, E. coli 0157:H7 was detected in enrichment cultures by a sandwich ELISA procedure.

The ELISA was performed in 96-well polystyrene EIA-RIA plates (GIBCO). Each well was coated with 100 µl of affinity purified goat antibody to E. coli 0157:H7 (10 µg/ml in 50 mM carbonate buffer, pH 9.6) [Kirkegaard and Perry Laboratories, Gaithersburg, Md.] and incubated at room temperature for 1 h or overnight. The antibody solution was removed by aspiration and the remaining binding sites were blocked with milk diluent/blocking solution [Kirkegaard and Perry Laboratories] for 15 min at room temperature. Blocking agent was removed and 300 µl of enrichment culture was added per well and incubated at 37°C for 45 min. After washing the wells three times with 50 mM Tris, pH 7.5, containing 150 mM NaCl and 0.05% Tween-20 (TBS-T), 100 µl of MAb 4E8C12 (ascitic fluid diluted 1:6000 in TBS) was added and incubated at 37°C for 45 min. The wells were washed three times with TBS-T followed by the addition of 100 µl of goat anti-mouse IgG conjugated to horseradish peroxidase (1:1400 in TBS) [Kirkegaard and Perry Laboratories] and incubated at 37°C for 45 min. After washing the wells four times with TBS-T, 100 µl of 2,2'-azino-di[3-ethylbenzthiazoline sulfate]-peroxidase substrate was added per well and held at room temperature for 20 min. The reaction was stopped by adding 50 µl of 1% sodium dodecyl sulfate in TBS per well and the OD of each well was measured at 410 nm by a Dynatech MR600 microplate reader. An OD of 0.2 above background was considered as positive. In each assay, enrichment cultures of food samples without inoculated E.

-37-

coli 0157:H7 were included as controls, and these were used to establish background readings.

Samples positive by sandwich ELISA were considered presumptive positive for E. coli 0157:H7. E. coli 0157:H7 was then isolated from enrichment cultures by a cultural method. Decimal dilutions of enrichment cultures were made to 10⁻⁶ in 0.1% peptone water. Dilutions (0.1 ml) at 10⁻⁵ and 10⁻⁶ were surface plated onto MSA-MUG and incubated at 37°C for 16-18 h. The number of colonies which were sorbitol negative (white) and MUG-negative (no fluorescence under UV light) were recorded. Five sorbitol-negative, MUG-negative colonies were picked randomly and were confirmed as E. coli 0157:H7 according to biochemical properties with the API 20E miniaturized diagnostic kit (Analytab Products, Plainview, N.Y.), by serology with 0157 and H7 antisera (Difco, E. coli Reference Center, Pennsylvania State University, University Park PA), and by Vero cell cytotoxicity assay.

The sensitivity of the sandwich ELISA was determined using pure cultures of the five strains of E. coli 0157:H7 at levels ranging from 10³ to 10⁸ CFU/ml. Each strain was tested individually. Similar studies were done with enrichment cultures of ground beef and dairy products that were spiked after enrichment with different levels of each of the same five strains of E. coli 0157:H7. Uninoculated enrichment cultures were used as controls. Detection and isolation of E. coli 0157:H7 from retail ground beef and raw milk from farms. A total of 10⁷ fresh ground beef samples were obtained from several Madison, WI.-area grocery stores during a 5-week period (Dec 90-Jan 91). Also 115 raw milk samples from bulk tanks of 69 different farms were obtained. Samples were placed in coolers with ice and were assayed for naturally occurring E. coli 0157:H7 by the procedure described above within 1-2 h after being brought to the laboratory. E. coli 0157:H7 was isolated

-38-

from positive samples and isolates were confirmed as E. coli 0157:H7 using the methods described above. A three-tube most probable number procedure was used to quantitate the number of E. coli 0157:H7 in positive ground beef samples. Ground beef samples were added (25 g, 2.5 g and 0.25 g) to 225 ml, 247.5 ml and 250 ml of dmTSB-CA, respectively, in Stomacher bags (3 per sample size), and macerated by a Stomacher for 5 min. The samples were transferred to sterile 1-L Erlenmeyer flasks and incubated at 37°C for 18 h with agitation (150 rpm). The presence of E. coli 0157:H7 in positive cultures (flasks) was confirmed by streak plating a loopful of enrichment culture on MSA-MUG plates. The plates were incubated at 37°C for 16-18 h and white (sorbitol-negative), MUG-negative colonies were selected and verified as E. coli 0157:H7 by the confirmatory assays described above.

Results: A sandwich ELISA was developed for detecting E. coli 0157:H7 in enrichment cultures of food. The specificity of the ELISA was determined using several strains of E. coli 0157:H7 and E. coli 0157:non-H7. All 25 strains of E. coli 0157:H7 reacted strongly in ELISA, whereas E. coli 0157:H16, 0157:H19, 0157:H25, and 0157:H45 were all negative. The sensitivity of the assay was determined with E. coli 0157:H7 (five different strains tested individually) in pure culture and in enrichment cultures of foods. The minimum number of cells detectable in pure culture was in the range of 10^4 - 10^5 CFU/ml, as illustrated in Fig. 3, and in enrichment cultures of food spiked with different levels of E. coli 0157:H7 after enrichment was in the range of 10^5 - 10^6 E. coli 0157:H7/ml.

In order to increase the sensitivity of the assay, studies were done to enhance the expression of the antigens on the bacterial surface which are recognized by the MAb. Standard enrichment conditions for isolating E. coli 0157:H7 from foods have been culturing in mTSB at

-39-

37°C with agitation. Hence, results from studies with these conditions were used as the standard for comparison. The effect of two growth temperatures (30° and 37°C) and agitation of the enrichment culture on expression of these antigens is shown in Fig. 4. These variables had no substantive effect on enhancing expression of the relevant antigens as evidenced by no major decrease in sensitivity of the ELISA when compared to the standard conditions for enrichment. Growth of E. coli 0157:H7 in mTSB at 42°C was poor, hence it was not possible to obtain an adequate amount of cells for detection by ELISA.

Both acriflavin-HCl and casamino acids in mTSB had a major effect on increasing the sensitivity of the ELISA as illustrated in Fig. 5. Acriflavin-HCl at 10 mg/L decreased the detection limit from $10^4 - 10^5$ E. coli 0157:H7/ml to 10^3 cells/ml. Acriflavin-HCl at lower concentrations had no significant effect on decreasing the detection limit. Casamino acids at 0.5 or 1% also increased the sensitivity of the ELISA, but not as much as did the addition of acriflavin. However, the addition of casamino acids to mTSB had an extra benefit of increasing the growth rate of E. coli 0157:H7.

Several other substrates or growth factors also were evaluated for their effect on increasing the sensitivity of the ELISA. These included growth in TSB or antibiotic medium No. 3 (PAB) versus mTSB. mTSB was best both for growth of E. coli 0157:H7 and for greatest sensitivity of ELISA. The addition of 1% glucose, rhamnose, mannose, lactose or sucrose to mTSB had little effect on the sensitivity of ELISA. Similarly, the addition of iron supplements, such as sheep red blood cells (0.5-5%), FeCl₃ (5-50 mg/L), FeSO₄ (0.5 g/L), or Fe(NH₄)₂(SO₄)₂ (50 mg/L), had no detectable effect.

Studies to determine the efficacy of the enrichment-sandwich ELISA procedure to detect low levels of E. coli 0157:H7 in foods was done with five different

-40-

strains of E. coli 0157:H7 tested individually at an inoculum of 0.2 to 0.9 cells per gram in ground beef and a variety of dairy products. The results are presented below in Tables 4 and 5.

Table 5. Detection of E. coli 0157:H7 in inoculated dairy products by enrichment-ELISA procedure.

| 5 Sample | <u>E. coli</u> 0157:H7 counts ^a (CFU/ml) | No. <u>E. coli</u> 0157:H7 strains detected/No. strains tested | Range of OD ₄₁₀ of ELISA of enrichment culture ^b | Level of sensi- tivity of procedure |
|---------------------------|--|--|--|--|
| 10 Sharp Cheddar cheese | ND ^c | 4/5 | 0.83 to 0.93 | 0.8 to 0.9 CFU/g |
| Sharp Cheddar cheese | 3.5 x 10 ⁸ | 5/5 | 0.52 to 0.99 | 0.3 to 0.6 CFU/g |
| Mild Cheddar cheese | 4.7 x 10 ⁷ | 5/5 | 0.82 to 1.01 | 0.5 to 0.6 CFU/g |
| Brick Cheddar cheese | ND | 5/5 | 0.56 to 0.98 | 0.3 to 0.6 CFU/g |
| Swiss Cheese | ND | 5/5 | 0.53 to 1.09 | 0.3 to 0.6 CFU/g |
| 15 Colby Cheese | 3.7 x 10 ⁸ | 5/5 | 0.84 to 1.10 | 0.2 to 0.6 CFU/g |
| Pasteurized whole milk | 1.8 x 10 ⁸ | 5/5 | 0.92 to 1.17 | 0.4 to 0.9 CFU/ml |
| Pasteurized skim milk | 3.6 x 10 ⁷ | 5/5 | 0.97 to 1.15 | 0.4 to 0.9 CFU/ml |
| 20 Raw milk | 3.8 x 10 ⁶ | 5/5 | 0.55 to 0.89 | 0.5 to 0.9 CFU/ml |
| Raw milk | 4.4 x 10 ⁷ | 5/5 | 0.59 to 0.92 | 0.4 to 0.8 CFU/ml |

^aNo. of E. coli 0157:H7 in enrichment culture.²⁵ ^bBackground OD₄₁₀ ranged from 0.004 to 0.196. OD₄₁₀ of 0.2 above background was considered positive.^cND, not determined.

-43-

Inoculation-recovery studies revealed that the procedure could detect between 0.2 to 0.9 E. coli 0157:H7 per gram of ground beef (Table 4) or dairy product (Table 5). None of the products used for these studies had naturally-occurring E. coli 0157:H7. Aerobic plate counts of ground beef samples before inoculation ranged from 1.1×10^4 to 1×10^9 CFU/g. All strains of E. coli 0157:H7 inoculated at levels of 0.2 to 0.9 CFU/g were detected in 9 of 10 ground beef enrichment samples. Only one of five inoculated strains was detected in one ground beef sample; however, this beef had an exceptionally high APC (1×10^9 CFU/g) which is very abnormal. Ground beef with APC at this level is usually spoiled. The large number of spoilage bacteria in this sample likely suppressed the growth of E. coli 0157:H7 during enrichment.

E. coli 0157:H7 inoculated in beef or dairy products at 0.2 to 0.9 CFU/g grew in enrichment cultures to levels of 3.8×10^6 to 3.7×10^8 CFU/g. The initial pH of enrichment medium dmTSB-CA (used for ground beef) was 7.0, whereas that of dmTSB-CA-buf (used for dairy products) was 7.4. Following enrichment, the pH values were in the range of 6.5 to 6.8.

E. coli 0157:H7 was detected in 3 of 107 (2.8%) ground beef samples from Madison, WI.-area grocery stores. APC of these samples before enrichment ranged from 4.0×10^5 to 7.8×10^7 CFU/g. The number of E. coli 0157:H7 in enrichment cultures of positive samples ranged from 2.5×10^6 to 8.6×10^6 CFU/ml, and the OD₄₁₀ of ELISA of positive enrichment cultures were 0.53 to 1.10. The organism was isolated by cultural procedures from all 3 samples that were E. coli 0157:H7-positive by ELISA. MPN determinations revealed E. coli 0157:H7 populations of 0.4 to 1.5 cells/g in the three samples.

A survey of 115 raw milk samples from 69 different farms revealed E. coli 0157:H7 was detected in 13 samples and was culturally confirmed in 11 samples. These 11 samples came from 7 different farms. APC of all milk samples before enrichment ranged from 2.8×10^2 to 2.6×10^5 CFU/ml. The

-44-

OD₄₁₀ of ELISA of E. coli 0157:H7-positive enrichment cultures were 0.55 to 1.08.

5 It is understood that the present invention is not limited to the particular reagents, steps or methods disclosed herein. Instead it embraces all such modified forms thereof as come within the scope of the following claims:

-45-

What is claimed is:

1. A monoclonal antibody specific to E. coli 0157:H7 and E. coli 026:H11.
2. The monoclonal antibody of claim 1 further characterized as binding to the strains of E. coli 0157:H7 and E. coli 026:H11 listed in Table 2 of the specification.
3. A monoclonal antibody of claim 1 prepared from the hybridoma ATCC HB 10452.
4. A monoclonal antibody specific to an outer membrane protein, the outer membrane protein being harvestable from E. coli 0157:H7 or E. coli 026:H11 cells, the outer membrane protein being capable of reacting specifically with monoclonal antibodies prepared from the hybridoma ATCC HB 10452.
5. The monoclonal antibody of claim 4 further characterized in that it is a member of the subclass immunoglobulin G_{2a}.
6. The monoclonal antibody according to claim 4 further characterized in that it has a kappa light chain.
7. The hybridoma ATCC HB 10452.
8. A continuous cell line which produces monoclonal antibodies against E. coli 0157:H7 and E. coli 026:H11, comprising:
 - (a) a hybridoma formed by fusing a cell capable of producing monoclonal antibodies against E. coli 0157:H7 and E. coli 026:H11; and
 - (b) a myeloma cell.
9. A diagnostic kit for assaying the presence of E. coli 0157:H7 and/or E. coli 026:H11 comprising the monoclonal antibody of claim 1 in one or more containers and directions for its use.
10. The diagnostic kit of claim 9, wherein the monoclonal antibody is conjugated to a label.
11. The diagnostic kit of claim 10, wherein the label is selected from the group consisting of enzymes, radioisotopes, particulate labels, chromogens, fluorescers,

-46-

5 chemiluminescers, coenzymes, free radicals, and
bacteriophages.

12. The diagnostic kit of claim 9, wherein the monoclonal antibody is bound to a support.

13. A diagnostic kit for differentiating enterohemorrhagic E. coli 0157:H7 and/or 026:H11 from other E. coli and enteric pathogens based on an outer membrane protein (OMP) unique to enterohemorrhagic E. coli 0157:H7 and 026:H11
5 comprising the monoclonal antibody of claim 1 and directions for its use.

14. The diagnostic kit of claim 13 wherein the monoclonal antibody is produced by the hybridoma ATCC HB 10452.

15. An immunoassay method for the detection of E. coli 0157:H7 or E. coli 026:H11, which comprises:

- 5 a) contacting a sample suspected of containing E. coli 0157:H7 or E. coli 026:H11 with a monoclonal antibody that is specific to E. coli 0157:H7 and E. coli 026:H11 in order to form an immune complex, and
b) determining the presence of the complex in order to detect E. coli 0157:H7 or E. coli
10 026:H11 in the sample.

16. The method of claim 15, wherein the monoclonal antibody is prepared from the hybridoma ATCC HB 10452.

17. The method of claim 15, wherein the monoclonal antibody is conjugated to a label.

18. A bioreagent for antibody assays comprising a substantially pure protein found in the outer membrane of E. coli 0157:H7 or E. coli 026:H11, said protein being further capable of reacting specifically with monoclonal antibodies to
5 E. coli 0157:H7 and E. coli 026:H11.

19. A substantially pure outer membrane protein harvestable from E. coli 0157:H7 or E. coli 026:H11 cells, the outer membrane protein being capable of reacting specifically with monoclonal antibodies prepared from the hybridoma ATCC HB
5 10452.




FIGURE 1

2/5




FIGURE 2

3/5




FIGURE 3

4/5




FIGURE 4




FIGURE 5

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/05310

| I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): G01N 33/569, 33/53, 33/532 U.S. CL.: 435/7.37, 240.27; 436/548; 530/387 | | | | | | | | | | | |
|---|--|-------------------------------------|--|--|--|---|--|------|---|--|------|
| II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; border: 1px solid black; text-align: left;">Classification System</th> <th style="border: 1px solid black; text-align: left;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">U.S.</td> <td style="border: 1px solid black; vertical-align: top;">435/7.37, 240.27, 172.2, 7.9, 7.37, 975, 849; 436/548; 530/387</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div> <p>STN Online Databases (File Biosis, 1969-1991, File Medine, 1972-1991). Automated Patent System (File USPAT, 1975-1991). See the attachment.</p> | | | Classification System | Classification Symbols | U.S. | 435/7.37, 240.27, 172.2, 7.9, 7.37, 975, 849; 436/548; 530/387 | | | | | |
| Classification System | Classification Symbols | | | | | | | | | | |
| U.S. | 435/7.37, 240.27, 172.2, 7.9, 7.37, 975, 849; 436/548; 530/387 | | | | | | | | | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; text-align: left;">Category [*]</th> <th style="width: 60%; text-align: left;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; text-align: left;">Relevant to Claim No. ¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">Biological Abstracts, Volume 89, No. 5. Issued 01 March 1990. V.V. Padhye, et al. "Production and characterization of monoclonal antibodies to verotoxins 1 and 2 from Escherichia coli of serotype O157:H7". the abstract no. 48707, J. Med. Microbiol.. 1989. 30(3). 219-226.</td> <td style="vertical-align: top;">1-19</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">Gastroenterology, vol. 94, No. 9, Issued March 1988. S. Tzipori, et al.. "Studies in Gnotobiotic Piglets on Non-o157:H7 Escherichia coli Serotypes isolated from Patients with Hemorrhagic colitis". pp. 590-597, see the abstract.</td> <td style="vertical-align: top;">1-19</td> </tr> </tbody> </table> | | | Category [*] | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | X | Biological Abstracts, Volume 89, No. 5. Issued 01 March 1990. V.V. Padhye, et al. "Production and characterization of monoclonal antibodies to verotoxins 1 and 2 from Escherichia coli of serotype O157:H7". the abstract no. 48707, J. Med. Microbiol.. 1989. 30(3). 219-226. | 1-19 | A | Gastroenterology, vol. 94, No. 9, Issued March 1988. S. Tzipori, et al.. "Studies in Gnotobiotic Piglets on Non-o157:H7 Escherichia coli Serotypes isolated from Patients with Hemorrhagic colitis". pp. 590-597, see the abstract. | 1-19 |
| Category [*] | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | | | | | | | | | |
| X | Biological Abstracts, Volume 89, No. 5. Issued 01 March 1990. V.V. Padhye, et al. "Production and characterization of monoclonal antibodies to verotoxins 1 and 2 from Escherichia coli of serotype O157:H7". the abstract no. 48707, J. Med. Microbiol.. 1989. 30(3). 219-226. | 1-19 | | | | | | | | | |
| A | Gastroenterology, vol. 94, No. 9, Issued March 1988. S. Tzipori, et al.. "Studies in Gnotobiotic Piglets on Non-o157:H7 Escherichia coli Serotypes isolated from Patients with Hemorrhagic colitis". pp. 590-597, see the abstract. | 1-19 | | | | | | | | | |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div> | | | | | | | | | | | |
| IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-right: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; border: 1px solid black; padding: 2px;">30 October 1991</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; border: 1px solid black; padding: 2px;">13 NOV 1991</div> </td> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;"> International Searching Authority <div style="text-align: center;">ISA/US</div> </td> <td style="padding: 5px;"> Signature of Authorized Officer <div style="text-align: center;"> Toni R. Scheiner </div> </td> </tr> </table> | | | Date of the Actual Completion of the International Search <div style="text-align: center; border: 1px solid black; padding: 2px;">30 October 1991</div> | Date of Mailing of this International Search Report <div style="text-align: center; border: 1px solid black; padding: 2px;">13 NOV 1991</div> | International Searching Authority <div style="text-align: center;">ISA/US</div> | Signature of Authorized Officer <div style="text-align: center;"> Toni R. Scheiner </div> | | | | | |
| Date of the Actual Completion of the International Search <div style="text-align: center; border: 1px solid black; padding: 2px;">30 October 1991</div> | Date of Mailing of this International Search Report <div style="text-align: center; border: 1px solid black; padding: 2px;">13 NOV 1991</div> | | | | | | | | | | |
| International Searching Authority <div style="text-align: center;">ISA/US</div> | Signature of Authorized Officer <div style="text-align: center;"> Toni R. Scheiner </div> | | | | | | | | | | |

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No |
|------------|--|----------------------|
| Y | Journal of Clinical Microbiology, Volume 26, No. 10, Issued October 1988 L.P. Perera, et al., "Isolation and Characterization of Monoclonal antibodies to Shiga-Like Toxin II of Enterohemorrhagic Escherichia coli and use of the Monoclonal antibodies in a colony Enzyme-Linked Immunosorbent Assay, pp. 2127-2131, see the Abstract. | 1-19 |

PCT/US91/05310

Attachment to PCT/ISA/210, part II.

II. Fields Searched/Search terms:

coli

enterohemorrhagic

0157:H7

026:H11

H7

H11

monoclonal

0157

026